Bristol-Myers Squibb




"Squibb" redirects here. It is not to be confused with Squib (disambiguation).






























































Bristol-Myers Squibb Company
Type
 Public
Traded as
NYSE: BMY
S&P 100 component
S&P 500 component
Industry Pharmaceuticals
Founded 1887
Headquarters
345 Park Avenue
New York, New York, United States
Key people
Giovanni Caforio, M.D.
(Chairman & CEO)
Charles Bancroft
(CFO)
Revenue IncreaseUS$ 20.78 billion (2017)
Operating income
 DecreaseUS$ 5.13 billion (2017)
Net income
 DecreaseUS$ 975 million (2017)
Total assets DecreaseUS$ 33.55 billion (2017)
Total equity DecreaseUS$ 11.85 billion (2017)
Number of employees
 ~23,700 (2017)
Website BMS.com

Footnotes / references
[1]

Bristol-Myers Squibb Company (BMS) is an American pharmaceutical company, headquartered in New York City.


Bristol-Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.


BMS' primary R&D sites are located in Lawrence, New Jersey (formerly Squibb, near Princeton), Hopewell Township and New Brunswick, New Jersey; with other sites in East Syracuse, New York, Cambridge, Massachusetts, Swords, Ireland, Braine-l'Alleud, Belgium, Tokyo, Japan, and Bangalore, India.[2] BMS previously had an R&D site in Wallingford, Connecticut (formerly Bristol-Myers).[3]




Contents






  • 1 History


    • 1.1 Squibb


    • 1.2 Bristol-Myers


    • 1.3 Merger


    • 1.4 2000 to 2010


    • 1.5 2011 onward


      • 1.5.1 Acquisition of Celgene




    • 1.6 Acquisition history




  • 2 Finances


  • 3 Pharmaceuticals


    • 3.1 Out of production


    • 3.2 Divested brands




  • 4 Products under development


  • 5 See also


  • 6 Notes and references


  • 7 External links





History



Squibb


The Squibb corporation was founded in 1858 by Edward Robinson Squibb in Brooklyn, New York. Squibb was known as a vigorous advocate of quality control and high purity standards within the fledgling pharmaceutical industry of his time, at one point self-publishing an alternative to the U.S. Pharmacopeia (Squibb's Ephemeris of Materia Medica) after failing to convince the American Medical Association to incorporate higher purity standards. Mentions of the Materia Medica, Squibb products, and Edward Squibb's opinion on the utility and best method of preparation for various medicants are found in many medical papers of the late 1800s.[4][5][6][7][8][9] Squibb Corporation served as a major supplier of medical goods to the Union Army during the American Civil War, providing portable medical kits containing morphine, surgical anesthetics, and quinine for the treatment of malaria (which was endemic in most of the eastern United States at that time).[10]



Bristol-Myers


In 1887, Hamilton College graduates William McLaren Bristol and John Ripley Myers purchased the Clinton Pharmaceutical company of Clinton, New York. In 1898, they decided to rename it Bristol, Myers and Company. Following Myers' death in 1899, Bristol changed the name to the Bristol-Myers Corporation. The first nationally recognized product was Sal Hepatica, a laxative mineral salt in 1903. Its second national success was Ipana toothpaste, from 1901 through the 1960s.[11] Other divisions were Clairol (hair colors and haircare) and Drackett (household products such as Windex and Drano).


In 1943, Bristol-Myers acquired Cheplin Biological Laboratories, a producer of acidophilus milk in East Syracuse, New York, and converted the plant to produce penicillin for the World War II Allied forces. After the war, the company renamed the plant Bristol Laboratories in 1945 and entered the civilian antibiotics market, where it faced competition from Squibb, which had opened the world's largest penicillin plant in 1944 in New Brunswick, New Jersey.[11][12] Penicillin production at the East Syracuse plant was ended in 2005, when it became less expensive to produce overseas,[citation needed] but the facility continues to be used for the manufacturing process development and production of other biologic medicines for clinical trials and commercial use.[13]



Merger


Bristol-Myers and Squibb merged in 1989, with Bristol-Myers as the nominal survivor. The merged company became Bristol-Myers Squibb.


In 1999, President Clinton awarded Bristol-Myers Squibb the National Medal of Technology, the nation's highest recognition for technological achievement, "for extending and enhancing human life through innovative pharmaceutical research and development and for redefining the science of clinical study through groundbreaking and hugely complex clinical trials that are recognized models in the industry."



2000 to 2010


In 2002, the company was involved in a lawsuit of maintaining illegally a monopoly on Taxol, its cancer treatment, and it was again sued for the antitrust lawsuit 5 years later, which cost the company $125 million for settlement.[14]


The company was involved in an accounting scandal in 2002 that resulted in a significant restatement of revenues from 1999 to 2001. The restatement was the result of an improper booking of sales related to "channel stuffing" as the practice of offering excess inventory to customers to create higher sales numbers. The company has since settled with the United States Department of Justice and Securities and Exchange Commission, agreeing to pay $150 million while neither admitting nor denying guilt.[15]


On October 24, 2002, Bristol-Myers Squibb Co. restated earnings downward for parts of 2000 and 2001 while revising this year's earnings upward because of its massive inventory backlog imbroglio that spurred two government investigations.[16] On March 15, 2004, Bristol-Myers Squibb Co. adjusted upward its fourth-quarter and full-year 2003 results after reversing an earlier decision about how to deal with accounting errors made in prior years.[17] As part of a Deferred Prosecution Agreement, the company was placed under the oversight of a monitor appointed by the U.S. Attorney in New Jersey. In addition, the former head of the Pharma group, Richard Lane, and the ex-CFO, Fred Schiff, were indicted for federal securities violations.


An investigation of the company was made public in July 2006, and the FBI raided the company's corporate offices. The investigation centered on the distribution of Plavix and charges of collusion.[18] On September 12, 2006, the monitor, former Federal Judge Frederick B. Lacey, urged the company to remove then CEO Peter Dolan over the Plavix dispute. Later that day, BMS announced that Dolan would indeed step down.[19]


The Deferred Prosecution Agreement expired in June 2007 and the Department of Justice did not take any further legal action against the company for matters covered by the DPA. Under CEO Jim Cornelius, who was CEO following Dolan until May 2010, all executives involved in the "channel-stuffing" and generic competition scandals have since left the company.


In 2009, a major restructuring began focusing on the pharmaceutical business and biologic products, along with productivity initiatives and cost-cutting and streamlining business operations through a multi-year program of on-going layoffs. This was part of a business strategy launched in 2007 to transform the company from a large diversified pharma company to a specialty biopharma company, which also included the closure of half of their manufacturing facilities.[20]:19 As another cost-cutting measure Bristol-Myers also reduced subsidies for health-care to retirees and plans to freeze their pension plan at the end of 2009.[citation needed] In August, BMS acquired the biotechnology firm Medarex as part of the company's "String of Pearls" strategy of alliances, partnerships and acquisitions.[21] In November, Bristol-Myers Squibb announced that it was "splitting off" Mead Johnson Nutrition by offering BMY shareholders the opportunity to exchange their stock for shares in Mead Johnson. According to Bristol-Myers Squibb, this move was expected to further sharpen the company's focus on biopharmaceuticals.


BMS is a Fortune 500 Company (#114 in 2010 list). Newsweek's 2009 Green Ranking recognized Bristol-Myers Squibb as 8th among 500 of the largest United States corporations. Also, BMS was included in the 2009 Dow Jones Sustainability North America Index of leading sustainability-driven companies.


In October 2010, the company acquired ZymoGenetics, securing an existing product as well as pipeline assets in hepatitis C, cancer and other therapeutic areas. Lamberto Andreotti was named CEO this year; he had previously served as "president and COO responsible for all pharmaceutical operations worldwide."[22]



2011 onward


In 2011, Lou Schmukler joined the company as the president of global product development and design; Schmukler led the team that completed the company's strategic transformation to a specialty biopharmaceutical company that had begun in 2007.[20]:19 As of 2011, the company had a dozen manufacturing facilities and six product development sites.[20]:19


Bristol-Myers Squibb agreed to pay around $2.5 billion in cash to buy Inhibitex Inc. in attempt to compete with Gilead/Pharmasset to produce Hepatitis C drugs. The settlement will be finished in 2 months for its Inhibitex's shareholders acceptance of 126 percent premium price of its price over the previous 20 trading days ended on January 6.[23] On June 29, Bristol-Myers Squibb extended its portfolio of diabetes treatments when it agreed to buy Amylin Pharmaceuticals for around US$5.3 billion in cash and pay US$1.7 billion to Eli Lilly to cover Amylin's debt and its outstanding collaboration-related obligations.[24]AstraZeneca, who already collaborated on several diabetes treatments with Bristol-Myers Squibb, agreed to pay US$3.4 billion in cash for the right to continue development of Amylin's products.[24] Two years later, in 2014, the company divested Amylin to AstraZeneca.[20]:19


Citing major developments and a market capitalization of US$87 billion and stock appreciation of 61.4%, Bristol-Myers Squibb was ranked as the best drug company of 2013 by Forbes Magazine.[25]


In April 2014, BMS announced its acquisition of iPierian for up to $725 million.[26] In December the company received FDA approval for the use of the PD-1 inhibitor nivolumab (Opdivo) in treating patients whose skin cancer cannot be removed or have not responded to previous drug therapies.[27] In February 2015, the company acquired Flexus Biosciences for $1.25 billion as well as initiating a research partnership with Rigel Pharmaceuticals which could generate more than $339 million. As part of the deal with Flexus, BMS will gain full rights to Flexus' lead small molecule IDO1-inhibitor, F001287.[28] In March, the company obtained an exclusive opportunity to both licence and commercialise PROSTVAC, Bavarian Nordic's phase III prostate specific antigen targeting cancer immunotherapy. Bavarian Nordic will receive an upfront payment of $60 million as well as incremental payments up to $230 million, if the overall survival of test patients exceeds that seen in Phase II tests. Bavarian could also receive milestone payments of between $110 million and $495 million, dependent on regulatory authorization, and these payments have the potential to total up to $975 million.[29]


In May 2015, Dr. Giovanni Caforio became CEO of the company;[30] Caforio was formerly the company's COO and succeeded Andreotti upon his retirement.[22] Andreotti subsequently succeeded James Cornelius as executive chairman upon his retirement.[22] In November, the company acquired the cardiovascular disease drug developer Cardioxyl for up to $2.075 billion. The deal strengthens the BMS' critical pipelines with the phase II candidate for acute decompensated heart failure, CXL-1427.[31]


In March 2016, the company announced it would acquire Padlock Therapeutics for up to $600 million.[32] In early July, the company announced it would acquire Cormorant Pharmaceuticals for $520 million, boosting BMS' onclogy offering through Cormorants monoclonal antibody targeted against interleukin-8.[33]


In late February 2017, the Wall Street Journal and Fortune - among others - reported that activist investor, Carl Icahn, had taken a stake in the company, signalling a potential future takeover[34][35] from the likes of Gilead Sciences.[36] In August the company acquired IFM Therapeutics for $300 million upfront, with contingency payments of $1.01 billion due on certain milestones – allowing BMS to better compete against Merck & Co's cancer rival treatment, Keytruda.[37]



Acquisition of Celgene


In early January 2019, the company announced it would acquire Celgene for $74 billion ($95 billion including debt[38]), in a deal that would become the largest pharmaceutical-company acquisition ever.[39] The Celgene acquisition aimed to be a refresher to the company's pipeline, helping to overcome from declining sales of Opdivo relative to competitor Keytruda.[40] Under the terms of the deal, Celgene shareholders would receive one BMS share as well as $50 in cash for each Celgene share held, valuing Celgene at $102.43 a share; representing a 54% premium to the previous days closing price.[41] Investor opposition to this acquisition, leading into an April 12 shareholder vote, appeared when BMS's second-largest investor, Wellington Management, voiced its opposition, followed by investor Starboard Value.[40]



Acquisition history


The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):


.mw-parser-output table.clade{border-spacing:0;margin:0;font-size:100%;line-height:100%;border-collapse:separate;width:auto}.mw-parser-output table.clade table.clade{width:100%}.mw-parser-output table.clade td{border:0;padding:0;vertical-align:middle;text-align:center}.mw-parser-output table.clade td.clade-label{width:0.8em;border:0;padding:0 0.2em;vertical-align:bottom;text-align:center}.mw-parser-output table.clade td.clade-slabel{border:0;padding:0 0.2em;vertical-align:top;text-align:center}.mw-parser-output table.clade td.clade-bar{vertical-align:middle;text-align:left;padding:0 0.5em}.mw-parser-output table.clade td.clade-leaf{border:0;padding:0;text-align:left;vertical-align:middle}.mw-parser-output table.clade td.clade-leafR{border:0;padding:0;text-align:right}







Bristol-Myers Squibb












 












 












 












 












 












 












 












 












 












 












 












 












 







 












 












 












 












 







 







 







 








Bristol-Myers Squibb












 

Squibb Corporation
(Founded 1858)
 
 

Bristol-Myers
(Founded 1887)
 
 
 
 
 
 
 







 

Adnexus Therapeutics[42]
(Acq 2007)
 
 
 
 







 

Bristol-Myers Squibb Medical Imaging[43]
(Sold to Avista Capital Partners 2007)
 
 
 
 







 

ConvaTec[44]
(Sold to Avista Capital Partners & Nordic Capital Fund VII 2008)
 
 
 
 







 

Kosan Biosciences[45]
(Acq 2008)
 
 
 
 
 







 

Medarex
(Acq 2009)
 
 
 
 







 

Mead Johnson
(Spun off 2009)
 
 
 
 







 

ZymoGenetics
(Acq 2010)
 
 
 
 







 

Amira Pharmaceuticals[46]
(Acq 2011)
 
 
 
 







 

Inhibitex Inc
(Acq 2012)
 
 
 
 







 

Amylin Pharmaceuticals
(Acq 2012 jointly with AstraZeneca)
 
 
 
 







 

iPierian
(Acq 2014)
 
 
 
 







 

Flexus Biosciences
(Acq 2015)
 
 
 
 







 

Cardioxyl
(Acq 2015)
 
 
 
 







 

Padlock Therapeutics
(Acq 2016)
 
 
 
 







 

Cormorant Pharmaceuticals
(Acq 2016)[33]
 
 
 
 







 

IFM Therapeutics
(Acq 2017)
 
 
 

Celgene







 













Juno Therapeutics
(Acq 2018)












 

AbVitro
(Acq 2016)
 
 

RedoxTherapies
(Acq 2016)
 
 
 












 

Impact Biomedicines
(Acq 2018)
 
 












 

Delinia
(Acq 2017)
 
 












 

EngMab AG
(Acq 2016)
 
 












 

Receptos
(Acq 2015)
 
 












 

Quanticel
(Acq 2015)
 
 












 

Avila Therapeutics, Inc
(Acq 2012)
 
 












 

Abraxis BioScience Inc
(Acq 2010)
 
 












 

Gloucester Pharmaceuticals
(Acq 2009)
 
 












 

Pharmion Corporation
(Acq 2008)
 
 












 

Anthrogenesis
(Acq 2002)
 
 












 

Signal Pharmaceuticals, Inc
(Acq 2000)
 
 







 

Celgene
(Spun off from
Celanese in 1986)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Finances


For the fiscal year 2017, Bristol-Myers Squibb reported earnings of US$1.007 billion, with an annual revenue of US$20.776 billion, an increase of 6.9% over the previous fiscal cycle. Bristol-Myers Squibb's shares traded at over $55 per share, and its market capitalization was valued at over US$81.6 billion in October 2018.[47] Bristol-Myers Squibb ranked 145th on the Fortune 500 list of the largest United States corporations by revenue in 2018.[48]



















































































































Year
 Revenue
in mil. USD$
 Net income
in mil. USD$
 Total Assets
in mil. USD$
 Price per Share
in USD$
 Employees
2005
 18,605
 3,000
 28,138
 14.60
2006
 16,208
 1,585
 25,575
 15.24
2007
 15,617
 2,165
 25,926
 18.98
2008
 17,715
 5,247
 29,486
 14.95
2009
 18,808
 10,594
 31,008
 15.90
2010
 19,484
 3,090
 31,076
 19.76
2011
 21,244
 3,701
 32,970
 23.41
2012
 17,621
 1,959
 35,897
 28.04
2013
 16,385
 2,563
 38,592
 38.39
 28,000
2014
 15,879
 2,004
 33,749
 47.03
 25,000
2015
 16,560
 1,565
 31,748
 59.63
 25,000
2016
 19,427
 4,457
 33,707
 59.73
 25,000
2017
 20,776
 1,007
 33,551
 55.88
 23,700


Pharmaceuticals


The following is a list of key pharmaceutical products:[49]



Cardiovascular diseases



  • Avalide (irbesartan/hydrochlorothiazide) — comarketed with Sanofi

  • Avapro (irbesartan) — comarketed with Sanofi

  • Coumadin (warfarin)

  • Eliquis (apixaban) — comarketed with Pfizer

  • Plavix (clopidogrel) — comarketed with Sanofi

  • Pravachol (pravastatin)


Diabetes mellitus



  • Bydureon (exenatide extended-release) — marketed by BMS only in some countries

  • Byetta (exenatide) — marketed by BMS only in some countries, such as Russian Federation

  • Farxiga/Forxiga (dapagliflozin)

  • Glucophage (metformin) — marketed by BMS only in USA

  • Glucophage XR (metformin extended release) — marketed by BMS only in USA

  • Glucovance (Glyburide/metformin)— marketed by BMS only in USA

  • Kombiglyze XR/Komboglyze (saxagliptin/metformin extended release) — comarketed with AstraZeneca

  • Onglyza (saxagliptin) — comarketed with AstraZeneca


Infectious diseases, including HIV infection and associated conditions




  • Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) — comarketed with Gilead Sciences

  • Azactam (aztreonam)

  • Baraclude (entecavir)

  • Daklinza (daclatasvir)

  • Evotaz (atazanavir/cobicistat)

  • Megace (megestrol acetate)

  • Reyataz (atazanavir)

  • Sustiva/Stocrin (efavirenz)

  • Videx (didanosine)

  • Videx EC (didanosine delayed-release)

  • Zerit (stavudine)


Inflammatory disorders



  • Kenalog-10 (triamcinolone acetonide)

  • Kenalog-40 (triamcinolone acetonide)


Oncology



  • BiCNU (carmustine)

  • CeeNU (lomustine)

  • Droxia/Hydrea (hydroxycarbamide)

  • Empliciti (Elotuzumab)

  • Erbitux (cetuximab)

  • Etopophos (etoposide)

  • Ixempra (ixabepilone)

  • Lysodren (mitotane)

  • Megace (megestrol acetate)

  • Opdivo (nivolumab) is a programmed death receptor blocking antibody used for the treatment of unresectable or metastatic melanoma and metastatic squamous non-small-cell lung carcinoma. In contrast to traditional chemotherapies and targeted anti-cancer therapies, which exert their effects by direct cytotoxic or tumor growth inhibition, nivolumab acts by inducing the immune system to attack the tumor.[50]

  • Sprycel (dasatinib)

  • Taxol (paclitaxel). At one time, BMS held the solitary contract to harvest the bark of endangered yew trees on United States territory for the manufacture of chemotherapy drug paclitaxel (Taxol). Current paclitaxel production comes from renewable sources.[citation needed] BMS also held the original paclitaxel license, but there are now multiple generic producers.[51]

  • Vumon (teniposide)

  • Yervoy (ipilimumab)


Psychiatry


  • Abilify (aripiprazole comarketed with Otsuka Pharmaceutical)

Rheumatic disorders


  • Orencia (abatacept)

Transplant rejection


  • Nulojix (belatacept)



Out of production



  • Sal Hepatica

  • Ipana



Divested brands


(Former Bristol-Myers brands, now divested)



  • Bufferin


  • Excedrin[52]

  • Ban Deodorant


  • Vitalis (hair tonic)[53]


  • Ammens (medicated power)


  • Final Net (hair spray)


  • Comtrex (cold relief capsules)


  • Keri (lotion)[54]



Products under development


The following is a selective list of investigational products under development, as of 2015:[55]




  • Beclabuvir (BMS-791325) — phase III


  • BMS-906024 — phase I


  • BMS-955176 — phase II


  • Brivanib alaninate (BMS-582664) — development terminated


  • Elotuzumab (BMS-901608) — phase III


  • Fostemsavir (BMS-663068) — phase III


  • Lirilumab (BMS-986015)


  • Lulizumab pegol (BMS-931699) — phase II



See also


  • Biotech and pharmaceutical companies in the New York metropolitan area


Notes and references





  1. ^ "US SEC: Form 10-K Bristol-Myers Squibb Company". U.S. Securities and Exchange Commission. Retrieved February 17, 2018..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"""""""'""'"}.mw-parser-output .citation .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}


  2. ^ "Bristol-Myers Squibb and Biocon's Syngene open new R&D Facility at Biocon Park". Archived from the original on 29 September 2012. Retrieved 16 May 2012.


  3. ^ "Bristol-Myers Squibb to lay off 149 as Wallingford, Connecticut, site nears closure". Fiercepharma.com. Retrieved 3 February 2019.


  4. ^ Hollopeter, W.C. (January 8, 1885). "Inverse Type of Temperature in Typhoid Fever, with a Report of Two Cases — Temperature Peculiarities in Epidemics, with a Report of Seven Cases in One Family". Boston Medical and Surgical Journal. 112: 28–32. doi:10.1056/NEJM188308301090903. Retrieved 2014-11-25. The writer noticed (in December, 1882) the important fact that when common or Japan camphor and crystallized carbolic acid are mixed together and subjected to heat, a colorless liquid would be the result. The only reference he finds so far with regard to this reaction occurs in the very excellent and valuable scientific publication of Dr. E. R. Squibb, " Ephemeris of Materia Medica", etc., on page 673, vol. ii., No. 5, where a brief allusion appears under the appellation of Compound Alum Powder. Dr. F. R. Squibb, however, in a letter to the writer states that he has " several times before heard of this reaction between phenol and camphor.


  5. ^ Bolles, William (August 30, 1883). "REPORT ON MATERIA MEDICA AND PHARMACY". Boston Medical and Surgical Journal. 109: 195–196. doi:10.1056/NEJM188308301090903. Retrieved 2014-11-25. Dr. Squibb is publishing in his Ephemeris a long and careful criticism upon the new Pharmacopoeia, four installments of which have already appeared, and are full of sound observation, and rich in practical pharmaceutical knowledge.


  6. ^ Worthen, Dennis (2003). "Edward Robinson Squibb (1819–1900): Advocate of Product Standards". Journal of the American Pharmacists Association. 46: 754–758. doi:10.1331/1544-3191.46.6.754. Archived from the original on 18 April 2014. Retrieved 25 November 2014.


  7. ^ Blake, J.B. (1899). "Administration of Ether at the Boston City Hospital". Boston Med Surg J. 141: 312–314. doi:10.1056/NEJM189909281411303. Until within six months Squibb's other has been exclusively used at the Boston City Hospital. Recently .MeliiHTéift's ether has been tried, ¡uni has given fair satisfaction ; Squibb's is still preferred by most of the house officers.


  8. ^ Brown, W.S. (1885). "Forty Year's Experience in Midwifery". Boston Medical and Surgical Journal. 112: 241. doi:10.1056/nejm188503121121101. One reason why ergot has fallen into disrepute is the poor quality of many specimens offered for sale. Dr. Squibb's aqueous extract rarely disappoints me.


  9. ^ Blodgett, Albert (October 27, 1887). "Reports of Societies: Massachusetts Medical Society. Suffolk District. Section for Clinical Medicine, Pathology and Hygiene". Boston Medical and Surgical Journal. 117: 408–413. doi:10.1056/NEJM188710271171706. Retrieved 2014-11-25. Dr. Farlow replied that he has had no trouble with any of the standard preparations of this drug, as manufactured by responsible firms. He mentioned Parke, Davis, & Co., Squibb, Metcalf, and a few others, whose preparations he had found to be reliable, and of uniform character.


  10. ^ Smith. Medicines for the Union Army: the United States Army laboratories during the Civil War. Accessed 2014-11-25.


  11. ^ ab Bert Rosenbloom, Marketing Channels, Bristol-Myers Squibb, 2011, page 609


  12. ^ "Bristol-Myers Squibb". Drugwatch. February 25, 2016. Retrieved November 14, 2016.


  13. ^ Bristol-Meyers Squibb, Syracuse, New York


  14. ^ "Bristol hit with antitrust suit". CNN. June 4, 2002. Retrieved Jul 10, 2013.


  15. ^ "Bristol-Myers Squibb Company : Lit. Rel. No. 18822" (Press release). US Securities and Exchange Commission. August 6, 2004. Retrieved May 9, 2015. Bristol-Myers inflated its results primarily by: (1) stuffing its distribution channels with excess inventory near the end of every quarter in amounts sufficient to meet sales and earnings targets set by officers ("channel-stuffing")


  16. ^ "Bristol-Myers to restate earnings as third quarter profits plunge". Archived from the original on 2013-11-05.


  17. ^ "Bristol-Myers restates results upward due to accounting errors". Archived from the original on 2015-09-24.


  18. ^ Business Report Archived 17 August 2007 at the Wayback Machine, July 31, 2006. Retrieved September 7, 2006. Archived at


  19. ^ CNN.com, September 12, 2006. Retrieved September 12, 2006


  20. ^ abcd Wright, Rob (October 2018). "From Big to Specialty—The Operational Transformation of Bristol-Myers Squibb". Life Science Leader. 10 (10). Erie, Pennsylvania: VertMarkets. Retrieved 17 October 2018.


  21. ^ https://finance.yahoo.com/news/BristolMyers-Squibb-to-bw-571310065.html?x=0&.v=1[permanent dead link]


  22. ^ abc Staff (15 February 2015). "BMS CEO Andreotti to Retire; COO named as Successor". Genetic Engineering & Biotechnology News (paper). 35 (4). p. 6.


  23. ^ "Bristol Buys Inhibitex for $2.5 Billion to Compete in Hepatitis". January 8, 2012.
    [permanent dead link]


  24. ^ ab Gershberg, Michele (30 June 2012). "Bristol-Myers to buy Amylin for about USD 5.3 billion". Reuters.


  25. ^ Herper, Matthew (December 31, 2013). "Grading Pharma in 2013". Forbes.


  26. ^ "Bristol-Myers to buy iPierian". Genetic Engineering & biotechnology news. April 29, 2014.


  27. ^ Anna Edney (22 December 2014). "Bristol-Myers Drug Wins U.S. Approval to Treat Advanced Melanoma". Bloomberg.com.


  28. ^ "GEN – News Highlights:BMS Deals Add to its Immuno-Oncology Portfolio". GEN.


  29. ^ "Bavarian Nordic Could Tally up to $975 Million in Prostate Cancer Deal with BMS – GEN News Highlights – GEN". GEN.


  30. ^ Johnson, Linda A. "New CEO Takes Over Evolving Drugmaker Bristol-Myers Squibb". ABC News. Retrieved 6 May 2015.


  31. ^ "BMS to Buy Cardioxyl for Up to $2.075B". GEN.


  32. ^ "BMS to Acquire Padlock Therapeutics for Up to $600M". GEN.


  33. ^ ab "BMS Snags Cormorant Pharmaceuticals for Up to $520M (online title: BMS Acquires Cormorant Pharmaceuticals for Up to $520M)". News: Industry Watch (online: GEN News Highlights). Genetic Engineering & Biotechnology News. 36 (14): 10. August 2016.


  34. ^ "Bristol-Myers Squibb Shares Just Spiked on Reports of a Carl Icahn Stake". Fortune. Retrieved 23 May 2017.


  35. ^ Benoit, David; Rockoff, Jonathan D. (22 February 2017). "Carl Icahn Takes Stake in Bristol-Myers Squibb". Retrieved 23 May 2017 – via www.wsj.com.


  36. ^ "Making (good) deals is hard to do, Gilead CEO says, but he's working on it – FiercePharma". www.fiercepharma.com. Retrieved 23 May 2017.


  37. ^ Editorial, Reuters. "Bristol-Myers to buy IFM Therapeutics to strengthen cancer pipeline".


  38. ^ https://uk.reuters.com/article/uk-celgene-m-a-bristol-myers/celgene-bristol-myers-set-2-2-billion-termination-fee-for-their-mega-deal-idUKKCN1OY1CA


  39. ^ https://www.bloomberg.com/news/articles/2019-01-03/bristol-myers-squibb-to-buy-celgene-in-74-billion-pharma-deal


  40. ^ ab Herbst-Bayliss, Svea; Erman, Michael (28 February 2019). "Starboard joins opposition to Bristol-Myers' $74 billion Celgene deal". Reuters. Retrieved 3 March 2019. Starboard reported on Thursday that it now owns 4.4 million shares, or 0.3 percent of Bristol’s outstanding shares, while Wellington owns an 8 percent stake.


  41. ^ https://www.bloomberg.com/news/articles/2019-01-03/bristol-myers-squibb-to-buy-celgene-in-74-billion-pharma-deal


  42. ^ "Bristol-Myers Squibb to Acquire Adnexus Therapeutics". bms.com.


  43. ^ "Avista Capital Partners Agrees to Acquire Bristol-Myers Squibb Medical Imaging for Approximately $525 Million". bms.com.


  44. ^ "Nordic Capital Fund VII and Avista Capital Partners Agree to Acquire ConvaTec Business for approximately $4.1 Billion". bms.com.


  45. ^ "Bristol-Myers Squibb to Acquire Kosan Biosciences". bms.com.


  46. ^ "Bristol-Myers Squibb to Acquire Amira Pharmaceuticals". bms.com.


  47. ^ "Bristol-Myers Squibb Revenue 2006-2018 | BMY". www.macrotrends.net. Retrieved 2018-10-31.


  48. ^ "Bristol-Myers Squibb". Fortune. Retrieved 2018-11-20.


  49. ^ "Selected Products of Bristol-Myers Squibb". © 2015 Bristol-Myers Squibb Company. Retrieved 30 May 2015.


  50. ^ Johnson DB, Peng C, Sosman JA (2015). "Nivolumab in melanoma: latest evidence and clinical potential". Ther Adv Med Oncol. 7 (2): 97–106. doi:10.1177/1758834014567469. PMC 4346215. PMID 25755682.


  51. ^ "Generic Taxol Availability". drugs.com.


  52. ^ "Bristol-Myers puts U.S. consumer brands on block – Jan. 12, 2005".


  53. ^ "Bristol-Myers Squibb to Divest Three Consumer Brands". Bristol-Myers Squibb Company. 21 September 1998.


  54. ^ "Bristol-Myers Squibb Plans To Divest U.S. And Canadian Consumer Medicines Business – Business Wire". 12 January 2005.


  55. ^ "Bristol-Myers Squibb: the Pipeline". © 2015 Bristol-Myers Squibb Company. Retrieved 30 May 2015.




External links




  • "Bristol-Myers Squibb donates $6.9 million to benefit cancer patient". Drugstorenews.com.


    • Business data for Bristol-Myers Squibb: Google Finance

    • Yahoo! Finance

    • Reuters

    • SEC filings










-

這個網誌中的熱門文章

12.7 cm/40 Type 89 naval gun

圖片
12.7 cm/40 Type 89 naval gun Type 89 gun mounted on Chitose Type Naval gun anti-aircraft gun Place of origin Japan Service history In service 1932–45 Used by Imperial Japanese Navy Wars World War II Production history Designed 1928–32 Produced 1932–45 No.  built ~1500 Variants Type 88 Specifications Mass 3,100 kilograms (6,834 lb) Barrel length 5,080 millimeters (16 ft 8 in) (bore length) Shell Fixed Shell weight 20.9–23.45 kilograms (46.1–51.7 lb) Caliber 12.7-centimeter (5.0 in) Breech horizontal breech block Elevation -8° to +90° [1] Rate of fire 8-14 rounds per minute Muzzle velocity 720–725 meters per second (2,360–2,380 ft/s) Maximum firing range 9,440 meters (30,970 ft) at 90° (AA ceiling) 14,800 meters (48,600 ft) at 45° The 12.7 cm/40 Type 89 naval gun was a Japanese anti-aircraft (AA) gun introduced before World War II. It was the Imperial Japanese Navy's standard heavy AA
閱讀完整內容

University of Vienna

圖片
"Vienna University" redirects here. For Vienna University of Economics and Business, see Vienna University of Economics and Business. University of Vienna Universität Wien Type Public Established 1365 Budget € 544 million [1] Rector Heinz Engl Academic staff 6,765 Administrative staff 3,106 Students 94,000 [2] Postgraduates 16,490 Doctoral students 8,945 Location Main building, Vienna , Austria 48°12′47″N 16°21′35″E  /  48.21306°N 16.35972°E  / 48.21306; 16.35972 Coordinates: 48°12′47″N 16°21′35″E  /  48.21306°N 16.35972°E  / 48.21306; 16.35972 Campus Urban Colors Blue and White           Affiliations Campus Europae, EUA, UNICA Website www.univie.ac.at/en Data as of 2016 [update] The University of Vienna (German: Universität Wien ) is a public university located in Vienna, Austria. It was founded by Duke Rudolph IV in 1365 and is one of the oldest universities in the Ge
閱讀完整內容

Rikitea

圖片
Town in French Polynesia, France Rikitea Town Rikitea Location in French Polynesia Coordinates: 23°7′13″S 134°58′9″W  /  23.12028°S 134.96917°W  / -23.12028; -134.96917 Coordinates: 23°7′13″S 134°58′9″W  /  23.12028°S 134.96917°W  / -23.12028; -134.96917 Country   France Overseas collectivity   French Polynesia Territory Gambier Islands Island Mangareva Rikitea is a small town on Mangareva, which is part of the Gambier Islands in French Polynesia. A majority of the islanders live in Rikitea. [1] [2] The island was a protectorate of France in 1871 and was annexed in 1881. [3] Contents 1 History 2 Geography 3 Economy 4 Landmarks 5 Transportation 6 References 7 Bibliography 8 External links History The town's history dates to the era when the island was first settled with people from the Marquesas Islands in 1100 AD. Captain James Wilson of the London Missionary Society arrived in 1797 on Du
閱讀完整內容